Desensitization in HLA-Incompatible Kidney Recipients and Survival Robert A. Montgomery, M.D., D.Phil., Bonnie E. Lonze, M.D., Ph.D., Karen E. King, M.D.,

Slides:

Advertisements

Similar presentations

PRA = 36% (21/58) Anti-A11 and B44.

Advertisements

Acceptable mismatches based on structural epitopes on HLA molecules Toulouse, April 2, 2008.

Kidney Dialysis and Transplants

Journey to Transplant: How Patients Facing Organ Failure Get on the Transplant Waiting List Christine Lee, RN, BSN, CCTC Leeanne Shinn, RN UCLA Kidney.

Cells, tissues and organs All living organisms are made up of cells. Large numbers of cells group together to form tissue. Tissues can combine to form.

Transplant Immunology – A User’s Guide!! Dr Mary Keogan Consultant Clinical Immunologist & Medical Director, NHISSOT Beaumont Hospital.

DoH IVIG Workshop Update on usage in Transplantation and outcomes measurement Haifa Lyster Consultant Pharmacist – Transplant & VADs Royal Brompton & Harefield.

Role of Bortezomib in Kidney Transplantation Reference: Raghavan R, Jeroudi A, Achkar K, et al. Bortezomib in kidney transplantation. J Transplant. 2010;1–6.

Objectives Overview of HLA genes and their function

Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

The Significance of C4d Staining with Minimal Histologic Abnormalities

Antibody Detection Relevance of cII-Specific Antibody

… Rejection Transplantation Biology:. Kidney rejection:

USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.

The Deceased Donor Kidney Allocation System

Transplantation Immunology Laura Stacy March 22, 2006.

Living Donor Kidney Transplant. What does the evidence say about outcome ? Professor Peter J Conlon.

Kidney Transplant: A Realistic Chance for Elderly Patients Reference: Munnapradist S, Danovitch GM. Kidney transplants for the elderly: Hope or hype? Clin.

3.7 Organ Transplantation Performed since early 1800’s, 1 st blood transfusions First organ transplant (kidney) 1954 Transplantable organs: heart,liver,lung,pancreas,intestines.

CORR Report, 2012: CST Annual General Meeting S. Joseph Kim, MD, PhD, FRCPC Vice President, CORR Board of Directors Friday, February 24,

CB-1 PULMINIQ™ (cyclosporine, USP) Inhalation Solution Benefit-Risk/Conclusions Stephen Dilly, MD, PhD Chief Medical Officer Chiron | BioPharmaceuticals.

Monitoring HLA-specific antibodies

INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.

Kidney Failure Noadswood Science, Kidney Failure To know medical treatments for kidney failure Thursday, September 17, 2015.

Kidney Failure. Learning Objective Success Criteria To know about kidney failure Outline the problems that arise from kidney failure and discuss the use.

Treatment of Preformed Antibodies “Desensitization Protocols” Maria E. Rodrigo, MD Associate Director, Heart Transplantation Medstar Washington Hospital.

Tissue Typing. E VERYONE HAS SEVERAL ANTIGENS LOCATED ON THE SURFACE OF HIS / HER LEUKOCYTES : One particular group of these antigens is called the HLA.

Liver Xenotransplantation Comprehensive Development Program

CLS 2215 Principles of Immunohematology

Kidney Transplant vs Blood Type FIGHT!!. Overview.

Pages  When blood is given intraveneously  Usually donated blood  Transfusions are given for:  Blood loss due to injury  Surgery  To supplement.

Maximizing Kidney Paired Donation CSGF Fellows Conference 2005 Sommer Gentry, MIT Dorry Segev, M.D., Robert A. Montgomery, M.D., Ph.D. Johns Hopkins School.

UK Renal Registry 17th Annual Report Figure Percentage of patients waitlisted for a kidney transplant by renal centre, prior to or within two years.

Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.

Kidney transplant case Niels Marcussen Hans Dieperink Odense University Hospital.

Immunomodulation of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Renal Replacement Therapy Sasipha Tachaboon 1, Khajohn Tiranatanakul.

Kidney Disorders. Kidney Transplant Many consider this to be the best method of treating kidney disease. A transplant may offer the best chance.

Current Trends in Transplantation Karin True MD, FASN Assistant Professor UNC Kidney Center May 23, 2011.

Preparing for a Kidney Transplant: Five Things To Know and Do Niraj M Desai, MD Director of the Kidney and Pancreas Transplant Program Johns Hopkins Hospital.

KIDNEY TRANSPLANTATION ULKEM CAKIR, MD PROFESSOR OF MEDICINE/NEPHROLOGY WOMEN IN KIDNEY TRANSPLANTATION 722 KIDNEY TX.

Graham Lipkin September 23 rd 2014 West Midlands Renal Network Transplant Education & Audit.

Transplantation of Tissues and Organs

Pages  When blood is given intraveneously  Usually donated blood  Transfusions are given for:  Blood loss due to injury  Surgery  To supplement.

Poster Title Transplant Professionals' Views on the Participation of Compatible Pairs in Kidney Exchange Programs C. Durand 1, M-C. Fortin 1,2 1. Centre.

Autoimmune Diseases How Do the Immune Cells of the Body Know What to Attack and What Not To Attack ?

Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function R3 김동연 /Prof. 정경환 N Engl J Med 373;5 July 30, 2015.

BLOOD COMPATIBILITY.

Reference: Gloor J, Stegall MD

Management of sensitized patients in kidney transplantation.

Draft Organ Allocation Criteria. Factors affecting Allocation Medical need Length of waiting time: time a illness progressed to a point when transplant.

Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

Donor Matching of Kidney Transplantation

Anti-thymocyte Globulin (Rabbit)

Blood Typing Health Occupations.

XENOTRANSPLANTATION The transplantation of an organ or

Mechanism and Treatment of Antibody-Mediated Rejection

CASE PRESENTATION DR SANJAY MAITRA, DR DENISH SAVALIA,

Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation Johann Pratschke, Duska Dragun, Ingeborg A. Hauser,

Living unrelated donor kidney transplantation

Relationship between Mixed Chimerism and Clinical Tolerance after Combined Kidney and Hematopoietic Cell Transplantation using Total Lymphoid Irradiation.

Number of Grafts Performed by Country

Tissue and Organ Transplantation

Kidney allocation to highly sensitized patients

Interesting Case Conference

Transplantation Rejection of foreign tissue grafts is due to immune responses to alloantigens on the graft Blood group antigens Polymorphic MHC antigens.

Jayme E. Locke, MD, MPH American Journal of Kidney Diseases

Figure 1 Identification of anti-HLA antibodies

Living unrelated donor kidney transplantation

Does rituximab help in HLA desensitization for kidney transplantation?

Presentation transcript:

Desensitization in HLA-Incompatible Kidney Recipients and Survival Robert A. Montgomery, M.D., D.Phil., Bonnie E. Lonze, M.D., Ph.D., Karen E. King, M.D., Edward S. Kraus, M.D., Lauren M. Kucirka, Sc.M., Jayme E. Locke, M.D., M.P.H., Daniel S. Warren, Ph.D., Christopher E. Simpkins, M.D., M.P.H., Nabil N. Dagher, M.D., Andrew L. Singer, M.D., Ph.D., Andrea A. Zachary, Ph.D., and Dorry L. Segev, M.D., Ph.D. N Engl J Med 2011;365: R2 Kim seung min / Prof. Jeong Kyung hwan

Background Renal-replacement therapy  transplantation or dialysis Transplantation  longevity & lifestyle health care costs Patients have become sensitized to HLA Ex: transplantation, pregnancy, blood transfusion  positive cross-match  donor specific anti-HLA antibody  hyperacute rejection, antibody mediated rejection, high rates of organ loss

Background More than 20,000 candidates for kidney transplantation sensitized to HLA and may have a prolonged wait for a transplant  transplantation rate Death rate One solution is to perform live donor renal transplantation after the depletion of donor-specific anti-HLA antibodies. antibody depletion results in a survival benefit as compared with waiting for an HLA-compatible kidney is unknown.

Methods February 1998 ~~ December patients  HLA-incompatible live donor kidney transplantation positive complement -dependent cytotoxic flow-cytometric crossmatching donor-specific anti-HLA antibody on multiplex bead assay Desensitization group -Plasmapheresis was performed with the use of a centrifuge-driven cell separator -patients received intravenous cytomegalovirus immune globulin at a dose of 100 mg per kilogram of body weight.

Methods Escalating numbers of treatments were performed before and after transplantation on the basis of the level of donor-specific anti-HLA antibody at baseline. The goal of treatment was the conversion to a negative cytotoxic cross- match before transplantation plasmapheresis + low-dose intravenous immune globulin  desensitize 211 HLA-sensitized patients who subsequently underwent renal transplantation (treatment group)

Methods Treatment group plasmapheresis + low-dose intravenous immune globulin matched control groups patients on a waiting list for kidney transplantation continued to undergo dialysis (dialysis-only group) either dialysis or HLA-compatible transplantation (dialysis-or-transplantation group).

Result

91.1%, 67.2%, 51.5%, and 30.5%, in the dialysis-only group 93.1%, 77.0%, 65.6%, and 49.1%, in the dialysis-or-transplantation group

Conclusion Live-donor transplantation after desensitization provided a significant survival benefit for patients with HLA sensitization, as compared with waiting for a compatible organ. By 8 years, this survival advantage more than doubled. desensitization protocols may help overcome incompatibility barriers in live-donor renal transplantation.